V Square Quantitative Management LLC Raises Position in McKesson Co. (NYSE:MCK)

V Square Quantitative Management LLC increased its holdings in McKesson Co. (NYSE:MCK) by 4.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,182 shares of the company’s stock after buying an additional 53 shares during the period. V Square Quantitative Management LLC’s holdings in McKesson were worth $674,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Catalyst Financial Partners LLC boosted its holdings in McKesson by 5.8% in the 4th quarter. Catalyst Financial Partners LLC now owns 910 shares of the company’s stock valued at $519,000 after purchasing an additional 50 shares during the period. Avestar Capital LLC raised its position in McKesson by 20.3% in the 4th quarter. Avestar Capital LLC now owns 1,526 shares of the company’s stock worth $871,000 after purchasing an additional 258 shares during the period. MGB Wealth Management LLC raised its position in McKesson by 1.2% in the 4th quarter. MGB Wealth Management LLC now owns 3,395 shares of the company’s stock worth $1,935,000 after purchasing an additional 39 shares during the period. Castellan Group increased its position in shares of McKesson by 0.4% in the fourth quarter. Castellan Group now owns 10,244 shares of the company’s stock valued at $5,838,000 after acquiring an additional 44 shares during the period. Finally, Hemington Wealth Management increased its position in shares of McKesson by 18.6% in the fourth quarter. Hemington Wealth Management now owns 115 shares of the company’s stock valued at $65,000 after acquiring an additional 18 shares during the period. 85.07% of the stock is owned by institutional investors.

McKesson Stock Performance

Shares of MCK stock opened at $593.82 on Friday. McKesson Co. has a one year low of $464.42 and a one year high of $637.51. The company has a 50 day moving average price of $587.46 and a 200 day moving average price of $563.18. The firm has a market capitalization of $75.38 billion, a price-to-earnings ratio of 27.19, a price-to-earnings-growth ratio of 1.30 and a beta of 0.52.

McKesson (NYSE:MCK) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $8.03 EPS for the quarter, missing analysts’ consensus estimates of $8.60 by ($0.57). McKesson had a net margin of 0.82% and a negative return on equity of 181.26%. As a group, equities analysts forecast that McKesson Co. will post 32.69 EPS for the current fiscal year.

McKesson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 1st. Stockholders of record on Monday, March 3rd will be given a $0.71 dividend. This represents a $2.84 annualized dividend and a dividend yield of 0.48%. The ex-dividend date is Monday, March 3rd. McKesson’s dividend payout ratio (DPR) is currently 13.00%.

Insider Transactions at McKesson

In other news, EVP Leann B. Smith sold 188 shares of the business’s stock in a transaction on Wednesday, February 12th. The shares were sold at an average price of $609.59, for a total value of $114,602.92. Following the completion of the sale, the executive vice president now directly owns 1,051 shares in the company, valued at approximately $640,679.09. The trade was a 15.17 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 1,346 shares of company stock valued at $795,275 over the last ninety days. Corporate insiders own 0.11% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on MCK shares. Bank of America cut their target price on shares of McKesson from $680.00 to $650.00 and set a “buy” rating on the stock in a research note on Monday, January 6th. Mizuho assumed coverage on shares of McKesson in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $630.00 target price on the stock. StockNews.com downgraded shares of McKesson from a “strong-buy” rating to a “buy” rating in a research note on Friday. Morgan Stanley upped their target price on shares of McKesson from $612.00 to $642.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 17th. Finally, Evercore ISI boosted their price objective on shares of McKesson from $650.00 to $675.00 and gave the company an “outperform” rating in a report on Thursday, February 6th. Two research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $645.79.

About McKesson

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.